SEC Form 4 · accession 0001140361-17-003373
NEVRO CORP · NVRO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Michael Enxing
Officer — VP of Sales
Period of report
Jan 26, 2017
Accepted (ET)
Jan 30, 2017 · 12:32 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001444380
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jan 26, 2017 | M | 37,000 | $3.60 | A | 77,463 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $3.60 | Jan 26, 2017 | M | 37,000 | D | — | Dec 17, 2022 | Common Stock | 37,000 | 41,608 | D |
Explanation of responses
- F1Includes 2,500 restricted stock units.
- F2100% of the shares subject to the option are fully vested and exercisable.